[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hypertension-ph\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hypertension-ph":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,88,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644867","euvolemia-based-assessment-of-pulmonary-hypertension-in-stable-hemodialysis-patients-100644867",false,"NCT07676786","Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients","Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis","EU-PHASE-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* End-stage kidney disease on maintenance HD for ≥ 3 months.\n* Stable clinical condition (no hospitalization in last 30 days).\n* Able and willing to comply with study protocol.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere left-sided valvular disease.\n* Active pulmonary or cardiac decompensation.\n* Persistent hypervolemia after completion of the volume assessment and correction phase\n* Inability to undergo echocardiography or bioimpedance assessment.\n* Acute infection or inflammatory condition at the time of enrollment.\n* Inadequate echocardiographic window preventing reliable assessment","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.\n\nThis prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.\n\nIn participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.\n\nThe study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.",[25,26,27,28,29,30],"Pulmonary Hypertension (PH)","End Stage Kidney Disease (ESRD)","Hemodialysis Patients","Volume Overload","Volume Assessment","Hemodialysis",[32,30,33,34,28,35,36,37,38,39,40,41],"Pulmonary Hypertension","End-Stage Kidney Disease","Euvolemia","Volume Status","Echocardiography","Bioimpedance Spectroscopy","Interdialytic Weight Gain","Vascular Access","Blood Pressure Variability","Lung Ultrasound","NOT_YET_RECRUITING","2026-06-24",{"date":45,"type":46},"2026-06-30","ACTUAL",{"date":48,"type":21},"2026-07-01",{"date":50,"type":21},"2027-03-30",{"name":52,"class":53},"Stefan Lujinschi","OTHER",2,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":65,"studyType":22,"phases":4,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100634271","evaluation-of-the-bmpr2-activin-signaling-pathway-in-group-ii-pulmonary-hypertension-100634271","NCT07537517","Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.","Evaluation of the BMPR2-Activin Signaling Pathway as a Key Mediator in Group II Pulmonary Hypertension. BREATHE-PH Study","BREATHE-PH","Inclusion Criteria:\n\n* Older that 18 years\n* Heart failled patients with clinical indication for invasive hemodynamic assessment\n* Written consent\n\nExclusion Criteria:\n\n* Refulsl to sign the infomred consent\n* Presence of iodinated contrast allergy\n* Ineligibility for HT (for BREATHE-CT substudy)",{"count":64,"type":21},150,"12 Months","Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.\n\nFocusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology.\n\nIts aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD.\n\nWe will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment.\n\nClinical parameters, biomarkers, molecular profiles, and hemodynamic\u002Fechocardiographic variables will be analyzed.\n\nA nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls.\n\nWe will also assess reversibility of vascular remodeling one year after transplantation.\n\nResults may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.",[68,25,69],"Pulmonary Hypertension Due to Left Heart Disease","Heart Failure",[71,72,73,74,75,76],"BMPR2","Activin","cardiac transplant","pulomnary hypertension II","gene expression","microRNAs","RECRUITING","2026-04-16",{"date":80,"type":46},"2026-04-17",{"date":82,"type":46},"2025-11-01",{"date":84,"type":21},"2028-12-31",{"name":86,"class":53},"Hospital General Universitario Gregorio Marañon",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":95,"enrollmentInfo":96,"targetDuration":65,"studyType":22,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":87},"100633093","arterial-wave-energy-flux-and-multidimensional-recovery-in-patients-with-chronic-thromboembolic-pulmonary-hypertension-undergoing-balloon-pulmonary-angioplasty-100633093","NCT07522203","Arterial Wave Energy Flux and Multidimensional Recovery in Patients With Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty","WE FIX BPA","Inclusion Criteria:\n\n* Age 18-85 years.\n\nConfirmed diagnosis of CTEPH by a multidisciplinary CTEPH team and deemed eligible for BPA.\n\nHemodynamics compatible with pre-capillary PH according to current guidelines, as assessed by RHC (Right Heart Catheterization).\n\nTechnically inoperable CTEPH or persistent\u002Frecurrent PH following PEA (Pulmonary Endarterectomy).\n\nWritten informed consent.\n\nExclusion Criteria:\n\n* Predominant diagnosis of PH other than CTEPH or concomitant severe parenchymal lung disease.\n\nActive infection, uncontrolled systemic disease, active malignancy, or life expectancy \\\u003C 12 months.\n\nPregnant or lactating patients.\n\nAdvanced renal failure (e.g., eGFR \\\u003C 30 \\\\text{ mL\u002Fmin\u002F1.73 m\\^2}) or contraindications to contrast media (per institutional routine).\n\nInadequate image quality precluding reliable echocardiographic analysis.\n\nPressure tracings with significant artifacts hindering analysis or uncontrolled arrhythmia (e.g., atrial fibrillation with rapid ventricular response).\n\nDecompensated or hemodynamically unstable patients.\n\nAny other condition deemed clinically unsuitable by the investigator.","85 Years",{"count":97,"type":21},70,"The goal of this observational study is to learn if advanced heart pressure wave analysis (called WIA and REPA) can help track and predict clinical improvement in adults (aged 18-85) with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who are undergoing Balloon Pulmonary Angioplasty (BPA).\n\nThe main questions it aims to answer are:\n\nDo changes in these advanced heart pressure wave patterns relate to improvements in a patient's walking distance, heart function, and overall quality of life after BPA treatment?\n\nAre these new measurements more effective than standard heart pressure tests at showing how much a patient has truly improved?\n\nParticipants will:\n\nUndergo standard Balloon Pulmonary Angioplasty (BPA) sessions as part of their regular medical care for CTEPH.\n\nHave their heart pressure waves recorded through a catheter during the routine BPA procedure (this does not require any extra surgical steps).\n\nComplete walking tests (6-minute walk test), blood tests, and heart ultrasounds (echocardiography) before starting the treatment and after it is completed.\n\nFill out short surveys regarding their daily physical activity and quality of life.",[100,25],"CTEPH",[102,103,104],"Arterial Wave Energy","Hemodynamics","Balloon Pulmonary Angioplasty","2026-04-03",{"date":107,"type":46},"2026-04-13",{"date":109,"type":46},"2026-03-10",{"date":111,"type":21},"2028-05-01",{"name":113,"class":114},"Istanbul Mehmet Akif Ersoy Educational and Training Hospital","OTHER_GOV",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100159371","compera--compera-kids-100159371","NCT01347216","COMPERA \u002F COMPERA-KIDS","Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension","COMPERA","Inclusion Criteria:\n\n* All age groups (amendment dated 1 June 2013)\n* Written informed consent\n* Pulmonary hypertension (PH) of either\n\n  * PAH: idiopathic form (IPAH) or\n  * PAH associated with connective tissue diseases (PAH-CTD), with congenital heart defects (PAH-CHD), with HIV infection (PAH-HIV), or the portopulmonary form\n  * Chronic thromboembolic PH (CTEPH)\n  * PH in left heart diseases (with isolated diastolic dysfunction; with systolic dysfunction, other)\n  * PH in pulmonary disease (chronic obstructive pulmonary disease; interstitial fibrosis, etc.)\n  * \"Relative PH\" in CHD after cavopulmonary anastomosis or Fontan-type surgery, even without the classical pulmonary pressure criteria of PH.\n* Newly initiated (i.e. a maximum of 3 months before documentation for the first time) therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in mono- or combination therapy.\n\nExceptions: PAH-CHD patients can be included on maintenance or newly initiated PAH therapy (3-month rule dose not apply).\n\nPAH-CHD patients with severe pulmonary vascular disease (e.g. Eisenmenger physiology) irrespective of treatment with any PAH drugs are eligible for inclusion, too.\n\nExclusion Criteria:\n\n* Patients on maintenance therapy, i.e. previous treatment with any ERA\u002F PDE-5 inhibitor\u002Fprostacyclin\u002FsGC stimulator drug longer than 3 months before documentation for the first time (exception: PAH-CHD patients).","1 Week",{"count":125,"type":21},14000,"In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH\u002FPAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH\u002FPH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH\u002FPAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in \\>50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH.\n\nSince July 2013, also children of any age can be documented (COMPERA-KIDS).",[128,25],"Pulmonary Arterial Hypertension (PAH)",[130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163],"Drug treatment","Treatment pathways","Clinical routine","Registry","Treatment outcomes","Endothelin receptor antagonist","Phosphodiesterase-V inhibitor","Prostanoid","Sildenafil","Bosentan","Macitentan","Sitaxentan","Ambrisentan","Imatinib","Epoprostenol","Treprostinil","Iloprost","Infusion pump","Riociguat","soluble guanylate cyclase stimulator","Quality of life","Patient-related outcomes","Economic model","Adverse event","Safety","Combination therapy","Internet","Europe","Eisenmenger","Adults","Children","Selexipag","Baltic states","Risk","2025-08-22",{"date":166,"type":46},"2025-08-24",{"date":168,"type":46},"2007-07-01",{"date":170,"type":21},"2026-12-31",{"name":172,"class":53},"Technische Universität Dresden",7]